250 related articles for article (PubMed ID: 20336985)
1. Drugs for Alzheimer's disease.
Cranwell-Bruce LA
Medsurg Nurs; 2010; 19(1):51-3. PubMed ID: 20336985
[No Abstract] [Full Text] [Related]
2. Alzheimer's disease: emerging noncholinergic treatments.
Geriatrics; 2003 Feb; 58 Suppl():3-14, inside back cover. PubMed ID: 12599937
[TBL] [Abstract][Full Text] [Related]
3. FDA approves groundbreaking Alzheimer's drug.
Provider; 2004 Feb; 30(2):24, 27. PubMed ID: 14964917
[No Abstract] [Full Text] [Related]
4. [Mechanisms of action of Alzheimer medications].
Alhainen K
Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
[No Abstract] [Full Text] [Related]
5. Therapies for Alzheimer's disease.
Melnikova I
Nat Rev Drug Discov; 2007 May; 6(5):341-2. PubMed ID: 17539055
[No Abstract] [Full Text] [Related]
6. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterase inhibitors and memantine have a role in the treatment of Alzheimer's disease.
Rabins PV; Lyketsos CG
Nat Clin Pract Neurol; 2006 Nov; 2(11):578-9. PubMed ID: 17057739
[No Abstract] [Full Text] [Related]
8. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
9. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
10. Discontinuing Alzheimer's disease drug therapy: why, when, and how.
Crutchfield D
Director; 2008; 16(1):19-21. PubMed ID: 19343870
[TBL] [Abstract][Full Text] [Related]
11. [The clinical relevance of memantine use].
Sobów T
Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
[TBL] [Abstract][Full Text] [Related]
12. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
13. Memantine (Namenda) for moderate to severe Alzheimer's disease.
Ables AZ
Am Fam Physician; 2004 Mar; 69(6):1491-2. PubMed ID: 15053415
[No Abstract] [Full Text] [Related]
14. Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
Rook Y; Schmidtke KU; Gaube F; Schepmann D; Wünsch B; Heilmann J; Lehmann J; Winckler T
J Med Chem; 2010 May; 53(9):3611-7. PubMed ID: 20361801
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Schölzel-Dorenbos CJ;
Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
[TBL] [Abstract][Full Text] [Related]
17. [4/5 Alzheimer's disease].
Blond B
Soins; 2010 May; (745):51-2. PubMed ID: 20509497
[No Abstract] [Full Text] [Related]
18. Untangling the confusion. Alzheimer's management today.
Wheldon M
Adv Nurse Pract; 2005 May; 13(5):47-8, 50, 52. PubMed ID: 15898316
[No Abstract] [Full Text] [Related]
19. [The challenge of Alzheimer dementia].
Pharm Unserer Zeit; 2003; 32(1):77. PubMed ID: 12577765
[No Abstract] [Full Text] [Related]
20. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
